Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Trump sets fundraising record with $50.5M from Florida eventXi calls on Shaanxi to write new chapter in advancing Chinese modernizationChina's top political advisor stresses efforts in rural revitalizationHamas says UNSC resolution demanding Gaza truce shows Israel's isolationChina's top legislature to set up deputies affairs commissionJets score 4 goals in 1st period, beat Avalanche 7Active role of overseas Chinese hailed at eventStormy, snowy weather expected across Japan: weather agencyXi calls on Shaanxi to write new chapter in advancing Chinese modernizationChinese premier addresses opening of Summer Davos